Literature DB >> 18234534

Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.

Sophie Moreau-Marquis1, Bruce A Stanton, George A O'Toole.   

Abstract

The cystic fibrosis (CF) lung is chronically inflamed and infected by Pseudomonas aeruginosa, which is a major cause of morbidity and mortality in this genetic disease. Although aerosolization of Tobramycin into the airway of CF patients improves outcomes, the lungs of CF patients, even those receiving antibiotic therapy, are persistently colonized by P. aeruginosa. Recent studies suggest that the antibiotic resistance of P. aeruginosa in the CF lung is due to the formation of drug resistant biofilms, which are defined as communities of microbes associated with surfaces or interfaces, and whose growth is facilitated by thick and dehydrated mucus in the CF lung. In this review, we discuss some of the current models used to study biofilm formation in the context of biotic surfaces, such as airway cells, as well as the contribution of host-derived factors, including DNA, actin and mucus, to the formation of these microbial communities. We suggest that better in vitro models are required, both to understand the interaction of P. aeruginosa with the host airway, and as models to validate new therapeutics, whether targeted at bacteria or host.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234534      PMCID: PMC2542406          DOI: 10.1016/j.pupt.2007.12.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  47 in total

Review 1.  Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.

Authors:  N Høiby; H Krogh Johansen; C Moser; Z Song; O Ciofu; A Kharazmi
Journal:  Microbes Infect       Date:  2001-01       Impact factor: 2.700

2.  Experimental reproducibility in flow-chamber biofilms.

Authors:  A Heydorn; B K Ersbøll; M Hentzer; M R Parsek; M Givskov; S Molin
Journal:  Microbiology       Date:  2000-10       Impact factor: 2.777

3.  Extracellular DNA required for bacterial biofilm formation.

Authors:  Cynthia B Whitchurch; Tim Tolker-Nielsen; Paula C Ragas; John S Mattick
Journal:  Science       Date:  2002-02-22       Impact factor: 47.728

4.  CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.

Authors:  Torsten H Schroeder; Martin M Lee; Patrick W Yacono; Carolyn L Cannon; A Alev Gerçeker; David E Golan; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

6.  Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa.

Authors:  S J McCallum; J Corkill; M Gallagher; M J Ledson; C A Hart; M J Walshaw
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

7.  Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

Authors:  A M Jones; J R Govan; C J Doherty; M E Dodd; B J Isalska; T N Stanbridge; A K Webb
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

Review 8.  Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing.

Authors:  C Fuqua; M R Parsek; E P Greenberg
Journal:  Annu Rev Genet       Date:  2001       Impact factor: 16.830

9.  Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.

Authors:  Nadine Hoffmann; Baoleri Lee; Morten Hentzer; Thomas Bovbjerg Rasmussen; Zhijun Song; Helle Krogh Johansen; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  104 in total

Review 1.  Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections.

Authors:  Diana P Pires; Diana Vilas Boas; Sanna Sillankorva; Joana Azeredo
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Peptidoglycomics reveals compositional changes in peptidoglycan between biofilm- and planktonic-derived Pseudomonas aeruginosa.

Authors:  Erin M Anderson; David Sychantha; Dyanne Brewer; Anthony J Clarke; Jennifer Geddes-McAlister; Cezar M Khursigara
Journal:  J Biol Chem       Date:  2019-11-26       Impact factor: 5.157

3.  Pseudomonas aeruginosa interacts with epithelial cells rapidly forming aggregates that are internalized by a Lyn-dependent mechanism.

Authors:  Paola Lepanto; David M Bryant; Jéssica Rossello; Anirban Datta; Keith E Mostov; Arlinet Kierbel
Journal:  Cell Microbiol       Date:  2011-05-25       Impact factor: 3.715

4.  Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.

Authors:  Mohammad Doroudian; Andrew O'Neill; Ciaran O'Reilly; Aisling Tynan; Leona Mawhinney; Aoife McElroy; Shanice S Webster; Ronan MacLoughlin; Yuri Volkov; Michelle E Armstrong; George A O'Toole; Adriele Prina-Mello; Seamas C Donnelly
Journal:  Nanomedicine (Lond)       Date:  2020-11-26       Impact factor: 5.307

5.  Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents.

Authors:  Steven A Rogers; Robert W Huigens; John Cavanagh; Christian Melander
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

6.  New perspectives in nanotherapeutics for chronic respiratory diseases.

Authors:  Adriana Lopes da Silva; Fernanda Ferreira Cruz; Patricia Rieken Macedo Rocco; Marcelo Marcos Morales
Journal:  Biophys Rev       Date:  2017-09-15

7.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.

Authors:  Qianru Yu; Edward F Griffin; Sophie Moreau-Marquis; Joseph D Schwartzman; Bruce A Stanton; George A O'Toole
Journal:  J Antimicrob Chemother       Date:  2012-07-26       Impact factor: 5.790

Review 9.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

10.  Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Authors:  Alex H Gifford; Lisa A Moulton; Dana B Dorman; Gordana Olbina; Mark Westerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  Clin Transl Sci       Date:  2012-06-01       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.